Response Evaluation after Neoadjuvant Chemoradiation by Positron Emission Tomography-Computed Tomography for Esophageal Squamous Cell Carcinoma

다국어 초록 (Multilingual Abstract)

Purpose Parameters of positron emission tomography-computed tomography (PET-CT) were compared with the results of histopathologic examination in order to determine which can provide an objective indication of response after neoadjuvant chemoradiation for treatment of thoracic esophageal squamous cell carcinoma (SCC).

Materials and Methods Between August 2003 and January 2010, data on 25 patients who underwent neoadjuvant chemoradiation and subsequent resection for treatment of esophageal SCC were retrospectively reviewed. Changes in maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were analyzed by comparison with the histopathologic findings.

Results Pathologic complete remission (CR) for the main tumor was achieved in 11 patients.

Postradiation esophagitis was observed in 10 patients. SUVmax of the main tumor was significantly greater in the CR group than in the partial response (PR) group (p=0.039), while MTV and TLG of the main tumor were not (p=0.141 and p=0.349,respectively). The cut-off SUVmax value for CR was estimated as 72.1%, indicating significantly better accuracy than visual interpretation (p=0.045). Of the 48 involved lymph nodes, SUVmax and MTV of lymph nodes were significantly greater in the CR group than in the PR group (p=0.045 and p=0.014, respectively), while TLG was not (p=0.063). The cut-off value of SUVmax for prediction of CR in lymph nodes was calculated as 50.67%.

Conclusion PET-CT could be used for prediction of response to neoadjuvant treatment in thoracic esophageal SCC. SUVmax may be a more significant predictor for CR after neoadjuvant chemoradiation than TLG and MTV.

참고문헌 (Reference)

1 Juweid ME, "Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma" 25 : 571-578, 2007

2 Wieder HA, "Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment" 22 : 900-908, 2004

3 Sjoquist KM, "Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis" 12 : 681-692, 2011

4 Aiko S, "Reduction rate of lymph node metastasis as a significant prognostic factor in esophageal cancer patients treated with neoadjuvant chemoradiation therapy" 20 : 94-101, 2007

5 Fletcher JW, "Recommendations on the use of 18F-FDG PET in oncology" 49 : 480-508, 2008

6 Urba SG, "Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma" 19 : 305-313, 2001

7 van Persijn van Meerten EL, "RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline" 20 : 1456-1467, 2010

8 Hyun SH, "Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma" 17 : 115-122, 2010

9 Le Roux PY, "Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria" 38 : 1064-1071, 2011

10 Kim JH, "Preoperative hyperfractionated radiotherapy with concurrent chemotherapy in resectable esophageal cancer" 50 : 1-12, 2001

11 Geh JI, "Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer" 88 : 338-356, 2001

12 Brucher BL, "Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography" 233 : 300-309, 2001

13 Luu TD, "Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer" 85 : 1217-1223, 2008

14 Sendler A, "Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction" 182 : 167-177, 2010

15 Young H, "Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group" 35 : 1773-1782, 1999

16 Jones DR, "Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy" 85 : 1026-1032, 1999

17 Thurau K, "Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer" 35 : 608-616, 2011

18 Bollschweiler E, "Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer" 6 : 25-35, 2010

19 van Heijl M, "Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer" 253 : 56-63, 2011

20 Mamede M, "FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progressionfree survival in esophageal cancer: correlation with histopathology results" 30 : 377-388, 2007

21 Zuccaro G Jr, "Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer" 94 : 906-912, 1999

22 Bates BA, "Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma" 14 : 156-163, 1996

23 Poplin E, "Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037)" 5 : 622-628, 1987

24 Roedl JB, "Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT: comparison to histopathologic and clinical response evaluation" 89 : 278-286, 2008

25 Walsh TN, "A comparison of multimodal therapy and surgery for esophageal adenocarcinoma" 335 : 462-467, 1996